Roivant Sciences launches new Alyvant subsidiary
Alyvant will be focused on connecting de-identified patient data with physician data to connect patient populations with suitable medications.
After a no-good, very bad year, Axovant reshuffles the deck
Bad news has piled up at Axovant, including the poor showing of its Parkinsons/Lewy body drug, and now the CEO David Hung is out after a mere 10 months on the job.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Axovant hires ex-Medivation CEO as it nears Phase 3 Alzheimer’s readout
Axovant founder and CEO Vivek Ramaswamy has stepped back from the top job, passing the reins to David Hung as the company nears a Phase 3 data readout for its lead Alzheimer's drug candidate.
More Phase 3 disappointment in Alzheimer’s disease
Alzheimer's underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.
Recycling drugs: Roivant’s subsidiary model powers on
Roivant's search for overlooked and underpriced compounds continues, as it builds out more subsidiaries and completes enrollment on its first Phase 3 trial.